Market Cap | 13.74B | P/E | 41.42 | EPS this Y | -12.70% | Ern Qtrly Grth | -55.20% |
Income | 673.24M | Forward P/E | 7.90 | EPS next Y | 11.20% | 50D Avg Chg | -3.00% |
Sales | 2.24B | PEG | 2.24 | EPS past 5Y | 34.59% | 200D Avg Chg | -16.00% |
Dividend | 2.00% | Price/Book | 2.31 | EPS next 5Y | 3.20% | 52W High Chg | -31.00% |
Recommedations | 2.00 | Quick Ratio | 9.35 | Shares Outstanding | 448.13M | 52W Low Chg | 5.00% |
Insider Own | 13.05% | ROA | 3.45% | Shares Float | 387.70M | Beta | 0.46 |
Inst Own | 72.75% | ROE | 10.53% | Shares Shorted/Prior | 14.19M/14.28M | Price | 30.65 |
Gross Margin | 55.46% | Profit Margin | 30.09% | Avg. Volume | 2,432,067 | Target Price | 44.83 |
Oper. Margin | 50.19% | Earnings Date | Nov 6 | Volume | 1,837,290 | Change | -0.81% |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Goldman Sachs | Buy | Aug 14, 24 |
Morgan Stanley | Overweight | Jul 11, 24 |
UBS | Neutral | Jun 3, 24 |
B of A Securities | Buy | Apr 12, 24 |
JP Morgan | Overweight | Feb 20, 24 |
Goldman Sachs | Buy | Feb 20, 24 |
Morgan Stanley | Overweight | Nov 9, 23 |
Morgan Stanley | Overweight | Oct 11, 23 |
Morgan Stanley | Overweight | Aug 9, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
RIGGS RORY B | Director Director | Jan 02 | Sell | 27.95 | 470,000 | 13,136,500 | 20,099 | 01/04/24 |
Avara Management Ltd | 10% Owner 10% Owner | Dec 27 | Sell | 28.11 | 251,592 | 7,072,251 | 2,543,323 | 12/29/23 |
Coyne Terrance P. | EVP & CFO EVP & CFO | Aug 09 | Sell | 30.73 | 75,000 | 2,304,750 | 790,000 | 08/11/23 |
Coyne Terrance P. | EVP & CFO EVP & CFO | Jul 12 | Sell | 31 | 75,000 | 2,325,000 | 865,000 | 07/14/23 |
Lloyd George W. | EVP, Investments & C.. EVP, Investments & CLO | Jun 02 | Sell | 33.63 | 192,221 | 6,464,392 | 30,000 | 06/06/23 |
Legorreta Pablo G. | CEO, Chairman of the.. CEO, Chairman of the Board | May 24 | Buy | 32.2496 | 150,000 | 4,837,440 | 380,000 | 05/24/23 |
RIGGS RORY B | Director Director | May 22 | Sell | 32.82 | 1,750,000 | 57,435,000 | 6,762 | 05/22/23 |
RIGGS RORY B | Director Director | Mar 29 | Sell | 36.6 | 139,950 | 5,122,170 | 1,456,762 | 03/30/23 |
Lloyd George W. | EVP, Investments & C.. EVP, Investments & CLO | Mar 28 | Sell | 37.04 | 112,779 | 4,177,334 | 212,221 | 03/30/23 |
Lloyd George W. | EVP, Investments & C.. EVP, Investments & CLO | Feb 23 | Sell | 37.2663 | 25,000 | 931,658 | 325,000 | 02/27/23 |
Urist Marshall | EVP, Research & Inve.. EVP, Research & Investments | Feb 22 | Sell | 37.2965 | 23,333 | 870,239 | 46,667 | 02/24/23 |
RIGGS RORY B | Director Director | Dec 09 | Sell | 42.02 | 60,000 | 2,521,200 | 96,712 | 12/13/22 |
Coyne Terrance P. | EVP & CFO EVP & CFO | Nov 02 | Sell | 43.0629 | 5,500 | 236,846 | 964,500 | 11/04/22 |
Giuliani Mario Germano | Director Director | Sep 28 | Sell | 41.05 | 32,593 | 1,337,943 | 8,077,140 | 09/30/22 |
Giuliani Mario Germano | Director Director | Sep 22 | Sell | 41.1681 | 211,380 | 8,702,113 | 8,109,733 | 09/26/22 |
GG 1978 SICAF SIF S.A. - GG St... | 10% Owner 10% Owner | Sep 20 | Sell | 41.0201 | 267,815 | 10,985,798 | 21,426,170 | 09/22/22 |
Giuliani Mario Germano | Director Director | Sep 16 | Sell | 41.61 | 387,171 | 16,110,185 | 22,657,815 | 09/20/22 |
GG 1978 SICAF SIF S.A. - GG St... | 10% Owner 10% Owner | Sep 16 | Sell | 41.61 | 387,171 | 16,110,185 | 21,693,985 | 09/20/22 |
RIGGS RORY B | Director Director | Sep 14 | Sell | 42.31 | 100,000 | 4,231,000 | 276,712 | 09/15/22 |
Giuliani Mario Germano | Director Director | Sep 07 | Sell | 42.7 | 499,500 | 21,328,650 | 8,577,140 | 09/09/22 |
GG 1978 SICAF SIF S.A. - GG St... | 10% Owner 10% Owner | Sep 07 | Sell | 42.7 | 498,006 | 21,264,856 | 22,426,170 | 09/09/22 |
GG 1978 SICAF SIF S.A. - GG St... | 10% Owner 10% Owner | Aug 25 | Sell | 44 | 1,994 | 87,736 | 22,924,176 | 08/29/22 |
Giuliani Mario Germano | Director Director | Aug 25 | Sell | 44 | 500 | 22,000 | 9,076,640 | 08/29/22 |
RIGGS RORY B | Director Director | Aug 09 | Sell | 43.7294 | 45,000 | 1,967,823 | 376,712 | 08/11/22 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | Aug 09 | Sell | 43.92 | 20,854 | 915,908 | 201,114 | 08/11/22 |
Coyne Terrance P. | EVP & CFO EVP & CFO | Aug 01 | Sell | 43.1909 | 30,000 | 1,295,727 | 970,000 | 08/03/22 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | Jul 28 | Sell | 43.9676 | 4,046 | 177,893 | 221,968 | 08/01/22 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | Jul 25 | Sell | 43.28 | 75,100 | 3,250,328 | 226,014 | 07/27/22 |
Urist Marshall | EVP, Research & Inve.. EVP, Research & Investments | Jul 25 | Sell | 43.12 | 23,334 | 1,006,162 | 07/27/22 | |
RIGGS RORY B | Director Director | Jun 29 | Sell | 42.1746 | 30,000 | 1,265,238 | 421,712 | 06/29/22 |
Urist Marshall | EVP, Research & Inve.. EVP, Research & Investments | Jun 24 | Sell | 43.1875 | 23,333 | 1,007,694 | 23,334 | 06/24/22 |
Reddoch James F. | EVP & Chief Scientif.. EVP & Chief Scientific Officer | Jun 08 | Sell | 41.559 | 100,000 | 4,155,900 | 920,800 | 06/10/22 |
Reddoch James F. | EVP & Chief Scientif.. EVP & Chief Scientific Officer | May 27 | Sell | 41.0801 | 75,000 | 3,081,008 | 1,020,800 | 05/31/22 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | May 26 | Sell | 40.49 | 100,000 | 4,049,000 | 430,000 | 05/31/22 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | May 23 | Sell | 40.2677 | 100,000 | 4,026,770 | 530,000 | 05/25/22 |
Urist Marshall | EVP, Research & Inve.. EVP, Research & Investments | May 16 | Sell | 39.8507 | 23,333 | 929,836 | 46,667 | 05/16/22 |
RIGGS RORY B | Director Director | Mar 29 | Sell | 38.5887 | 60,000 | 2,315,322 | 601,712 | 03/30/22 |
RIGGS RORY B | Director Director | Mar 17 | Sell | 39.33 | 169,089 | 6,650,270 | 03/21/22 | |
Fernandez Henry A | Director Director | Feb 24 | Buy | 37.4884 | 32,500 | 1,218,373 | 58,200 | 02/25/22 |
RIGGS RORY B | Director Director | Dec 28 | Sell | 40.16 | 184,448 | 7,407,432 | 592,748 | 12/30/21 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | Nov 16 | Sell | 42.51 | 250,000 | 10,627,500 | 630,000 | 11/18/21 |
RIGGS RORY B | Director Director | Nov 16 | Sell | 42.28 | 214,389 | 9,064,367 | 1,115,645 | 11/18/21 |
RIGGS RORY B | Director Director | Jun 29 | Sell | 42.17 | 1,314,912 | 55,449,839 | 3,451,258 | 06/29/21 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | Jun 14 | Sell | 46.47 | 70,000 | 3,252,900 | 240,000 | 06/14/21 |
Urist Marshall | EVP & Co-Head of R&I EVP & Co-Head of R&I | Jun 08 | Sell | 46.08 | 33,134 | 1,526,815 | 06/08/21 | |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | Jun 04 | Sell | 42.11 | 62,500 | 2,631,875 | 1,050,000 | 06/04/21 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | Apr 16 | Sell | 42.13 | 69,822 | 2,941,601 | 200,000 | 04/16/21 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | Apr 14 | Sell | 42.32 | 449 | 19,002 | 255,898 | 04/14/21 |
Lloyd George W. | EVP, Investments & G.. EVP, Investments & GC | Mar 04 | Sell | 47.37 | 125,000 | 5,921,250 | 300,000 | 03/04/21 |
Reddoch James F. | EVP, Research & Inve.. EVP, Research & Investments | Mar 04 | Sell | 47.37 | 100,000 | 4,737,000 | 300,000 | 03/04/21 |